Pelthos Therapeutics Inc
Follow $PTHS
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $PTHS by emailVeridion Score
BETALOW CONF · 4 of 6 factors measuredsnapshot unavailable for PTHS. Cause unavailable.
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is PTHS moving today?
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
PTHS overview
Related filings and maps
Congress activity in PTHS
No receipt-qualified Congressional disclosure is present for PTHS in the cached public ledger.
PTHS contract awards, year to date.
Public federal awards linked to this ticker.
PTHS lobbying filings, year to date.
Registered lobbying filings matched to Pelthos Therapeutics Inc.